Imaging Characteristics of Oligodendrogliomas That Predict Grade

References

1. 1.↵
   1. Claus EB,
   2. Black PM

   . Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 2006;106:1358–63

   CrossRefPubMedWeb of Science
2. 2.↵
   1. McCarthy BJ,
   2. Propp JM,
   3. Davis FG,
   4. et al

   . Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 2008;30:34–44

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Koeller KK,
   2. Rushing EJ

   . From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation. Radiographics 2005;25:1669–88

   PubMed
4. 4.↵
   1. Shaw EG,
   2. Scheithauer BW,
   3. O'Fallon JR,
   4. et al

   . Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992;76:428–34

   PubMedWeb of Science
5. 5.↵
   1. Engelhard HH,
   2. Stelea A,
   3. Mundt A

   . Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003;60:443–56

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Dehghani F,
   2. Schachenmayr W,
   3. Laun A,
   4. et al

   . Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 1998;95:493–504

   CrossRefPubMed
7. 7.↵
   1. Earnest F 3rd.,
   2. Kernohan JW,
   3. Craig WM

   . Oligodendrogliomas: a review of 200 cases. Arch Neurol Psychiatry 1950;63:964–76

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Wislawski J

   . Cerebral oligodendrogliomas: clinical manifestations, surgical treatment and histological findings in seventy cases. Pol Med J 1970;9:163–72

   PubMed
9. 9.↵
   1. Louis DN,
   2. Ohgaki H,
   3. Wiestler OD,
   4. et al

   . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109. Epub 2007 Jul 6.

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Brasil Caseiras G,
    2. Ciccarelli O,
    3. Altmann DR,
    4. et al

    . Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology 2009;253:505–12

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Fortin D,
    2. Cairncross GJ,
    3. Hammond RR

    . Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999;45:1279–91, discussion 1191

    PubMedWeb of Science
12. 12.↵
    1. Lee YY,
    2. Van Tassel P

    . Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 1989;152:361–69

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Leonardi MA,
    2. Lumenta CB

    . Oligodendrogliomas in the CT/MR-era. Acta Neurochir (Wien) 2001;143:1195–203

    CrossRefPubMed
14. 14.↵
    1. Wu Z,
    2. Mittal S,
    3. Kish K,
    4. et al

    . Identification of calcification with MRI using susceptibility-weighted imaging: a case study. J Magn Reson Imaging 2009;29:177–82

    CrossRefPubMed
15. 15.↵
    1. Arvinda HR,
    2. Kesavadas C,
    3. Sarma PS,
    4. et al

    . Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 2009;94:87–96

    CrossRefPubMed
16. 16.↵
    1. Cha S,
    2. Tihan T,
    3. Crawford F,
    4. et al

    . Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266–73

    Abstract/FREE Full Text
17. 17.↵
    1. Chaskis C,
    2. Stadnik T,
    3. Michotte A,
    4. et al

    . Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study. Acta Neurochir (Wien) 2006;148:277–85, discussion 285

    CrossRefPubMed
18. 18.↵
    1. Alvord EC Jr.

    . Is necrosis helpful in the grading of gliomas? Editorial opinion. J Neuropathol Exp Neurol 1992;51:127–32

    PubMed
19. 19.↵
    1. Maia AC Jr.,
    2. Malheiros SM,
    3. da Rocha AJ,
    4. et al

    . Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg 2004;101:970–76

    PubMed
20. 20.↵
    1. Agresti A

    . Categorical Data Analysis. Hoboken, New Jersey: Wiley-Interscience; 2002
21. 21.↵
    1. Rosner B

    . Fundamentals of Biostatistics. Boston: Duxbury Press; 2006
22. 22.↵
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010
23. 23.↵
    1. Law M,
    2. Oh S,
    3. Johnson G,
    4. et al

    . Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099–107, discussion 1099–107

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Reiche W,
    2. Grunwald I,
    3. Hermann K,
    4. et al

    . Oligodendrogliomas. Acta Radiol 2002;43:474–82

    FREE Full Text
25. 25.↵
    1. White ML,
    2. Zhang Y,
    3. Kirby P,
    4. et al

    . Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 2005;26:784–90

    Abstract/FREE Full Text
26. 26.↵
    1. Kono K,
    2. Inoue Y,
    3. Nakayama K,
    4. et al

    . The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001;22:1081–88

    Abstract/FREE Full Text
27. 27.↵
    1. Sadeghi N,
    2. Camby I,
    3. Goldman S,
    4. et al

    . Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. AJR Am J Roentgenol 2003;181:235–41

    CrossRefPubMed
28. 28.↵
    1. Maia AC Jr.,
    2. Malheiros SM,
    3. da Rocha AJ,
    4. et al

    . MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777–83

    Abstract/FREE Full Text
29. 29.↵
    1. Law M,
    2. Yang S,
    3. Wang H,
    4. et al

    . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

    Abstract/FREE Full Text
30. 30.↵
    1. Whitmore RG,
    2. Krejza J,
    3. Kapoor GS,
    4. et al

    . Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007;107:600–09

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Spampinato MV,
    2. Smith JK,
    3. Kwock L,
    4. et al

    . Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204–12

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Lev MH,
    2. Ozsunar Y,
    3. Henson JW,
    4. et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
33. 33.↵
    1. Xu M,
    2. See SJ,
    3. Ng WH,
    4. et al

    . Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005;56:919–26, discussion 919–26

    PubMedWeb of Science
34. 34.↵
    1. Caseiras GB,
    2. Chheang S,
    3. Babb J,
    4. et al

    . Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol 2010;73:215–20

    CrossRefPubMed